Centre of Evidence Based Dermatology
  • Print

CEBD Coronavirus Dermatology Resource

 

Journal articles - Implications of coronavirus for use of biologics and other immune modulating therapies

 

Please see also Guidelines page

Intralesional antigen immunotherapy for warts in the era of COVID-19.
Nofal A, Fawzy MM, Abdelmaksoud A, El-Hawary EE.
J Dermatolog Treat. 2020 Aug 8:1-4. doi: 10.1080/09546634.2020.1808152. Online ahead of print. Commentary / recommendations.
https://doi.org/10.1080/09546634.2020.1808152

Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.
Gadarowski MB, Balogh EA, Bashyam AM, Feldman SR.
J Dermatolog Treat. 2020 Aug 8:1-17. doi: 10.1080/09546634.2020.1808154. Online ahead of print. Review.
https://doi.org/10.1080/09546634.2020.1808154

Biologic drugs during COVID-19 outbreak.
Montesu MA, Biondi G, Sotgiu G, Sucato F, Satta R.
Int J Dermatol. 2020 Aug 6. doi: 10.1111/ijd.15088. Online ahead of print. Cohort study.
https://doi.org/10.1111/ijd.15088

COVID-19 and immunosuppressive therapy in dermatology.
Schwartz RA, Pradhan S, Murrell DF, Jafferany M, Olisova OY, Lomonosov KM, Lotti T, Goldust M.
Dermatol Ther. 2020 Aug 7:e14140. doi: 10.1111/dth.14140. Online ahead of print. Review / recommendations.
https://doi.org/10.1111/dth.14140

COVID-19 and immunological regulations - from basic and translational aspects to clinical implications.
Schön MP, Berking C, Biedermann T, Buhl T, Erpenbeck L, Eyerich K, Eyerich S, Ghoreschi K, Goebeler M, Ludwig RJ, Schäkel K, Schilling B, Schlapbach C, Stary G, von Stebut E, Steinbrink K.
J Dtsch Dermatol Ges. 2020 Aug 6. doi: 10.1111/ddg.14169. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14169

Severe acute respiratory syndrome coronavirus 2 and the use of biologics in patients with psoriasis.
Ladda M, Lynde C, Fleming P.
J Cutan Med Surg. 2020 Aug 6:1203475420945234. doi: 10.1177/1203475420945234. Online ahead of print. Review.
https://doi.org/10.1177/1203475420945234

Systemic immunosuppression in times of COVID-19: Do we need to rethink our standards?
Grabbe S, Beissert S, Enk A.
J Dtsch Dermatol Ges. 2020 Aug 2. doi: 10.1111/ddg.14194. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14194

Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak.
Veenstra J, Buechler CR, Robinson G, Chapman S, Adelman M, Tisack A, Dimitrion P, Todter E, Kohen L, Lim HW.
J Am Acad Dermatol. 2020 Jul 28:S0190-9622(20)32290-8. doi: 10.1016/j.jaad.2020.07.089. Online ahead of print. Retrospective cohort study.
https://doi.org/10.1016/j.jaad.2020.07.089

Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
Kearns DG, Chat VS, Uppal S, Wu JJ.
J Am Acad Dermatol. 2020 Jul 28:S0190-9622(20)32287-8. doi: 10.1016/j.jaad.2020.07.086. Online ahead of print. Trial analysis / commentary.
https://doi.org/10.1016/j.jaad.2020.07.086

Impact of the COVID-19 pandemic on chronic inflammatory dermatoses: Mixed messages regarding the dermatologist's point of view and the patient's concerns.
Fougerousse AC, Maccari F, Reguiai Z, Begon E, Pallure V, Taïeb C, Girard C, Mery-Bossard L.
Acta Derm Venereol. 2020 Jul 31. doi: 10.2340/00015555-3610. Online ahead of print. Commentary.
https://doi.org/10.2340/00015555-3610

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K; PSO-BIO-COVID study group.
J Eur Acad Dermatol Venereol. 2020 Jul 31. doi: 10.1111/jdv.16841. Online ahead of print. Multicentre observational study.
https://doi.org/10.1111/jdv.16841

COVID-19 and implications for dermatological and allergological diseases.
Buhl T, Beissert S, Gaffal E, Goebeler M, Hertl M, Mauch C, Reich K, Schmidt E, Schön MP, Sticherling M, Sunderkötter C, Traidl-Hoffmann C, Werfel T, Wilsman-Theis D, Worm M.
J Dtsch Dermatol Ges. 2020 Jul 27. doi: 10.1111/ddg.14195. Online ahead of print. Review.
https://doi.org/10.1111/ddg.14195

How infodemic during the COVID-19 outbreak influenced common clinical practice in an Outpatient Service of severe psoriasis.
Sacchelli L, Evangelista V, Di Altobrando A, Lacava R, Rucci P, Rosa S, Patrizi A, Bardazzi F.
Dermatol Ther. 2020 Jul 26:e14065. doi: 10.1111/dth.14065. Online ahead of print. Prospective cohort study.
https://doi.org/10.1111/dth.14065

Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?
Megna M, Fabbrocini G, Marasca C.
Int J Dermatol. 2020 Jul 25. doi: 10.1111/ijd.15059. Online ahead of print. Commentary.
https://doi.org/10.1111/ijd.15059

The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies.
Pirro F, Caldarola G, Chiricozzi A, Tambone S, Mariani M, Calabrese L, D'Urso DF, De Simone C, Peris K.
J Dermatolog Treat. 2020 Jul 24:1-14. doi: 10.1080/09546634.2020.1800578. Online ahead of print. Survey / cross-sectional study.
https://doi.org/10.1080/09546634.2020.1800578

COVID 19 and immunosuppressants: An opinion pool of practising dermatologists of India.
Ray A, Debata I, Agrawal I, Panda M.
Dermatol Ther. 2020 Jul 22:e14036. doi: 10.1111/dth.14036. Online ahead of print. Survey.
https://doi.org/10.1111/dth.14036

Rituximab: a safe therapeutic option during the COVID-19 pandemic?
Di Altobrando A, Patrizi A, Abbenante D, Bardazzi F.
J Dermatolog Treat. 2020 Jul 22:1-3. doi: 10.1080/09546634.2020.1800565. Online ahead of print. Cross-sectional study.
https://doi.org/10.1080/09546634.2020.1800565

A case of severe psoriatic erythroderma with COVID-19.
Ghalamkarpour F, Pourani MR, Abdollahimajd F, Zargari O.
J Dermatolog Treat. 2020 Jul 21:1-11. doi: 10.1080/09546634.2020.1799918. Online ahead of print. Case report.
https://doi.org/10.1080/09546634.2020.1799918

Psoriasis and COVID-19: A narrative review with treatment considerations.
Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K, Akdeniz N, Atasoy M, Türsen Ü, Lotti T.
Dermatol Ther. 2020 Jun 17:e13858. doi: 10.1111/dth.13858. Online ahead of print.
https://doi.org/10.1111/dth.13858

Treatment discontinuation and rate of disease transmission in psoriasis patients on biologic therapy during the COVID-19 pandemic - A Canadian multicenter retrospective study.
Georgakopoulos JR, Mufti A, Vender R, Yeung J.
J Am Acad Dermatol. 2020 Jul 14. pii: S0190-9622(20)32185-X. doi: 10.1016/j.jaad.2020.07.021. [Epub ahead of print] No abstract available. Retrospective study / case review.
https://doi.org/10.1016/j.jaad.2020.07.021

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
Vispi M, Corradin T, Peccianti C, Feci L, Casini L, Pisani C, Fabbroni S, Corsetti P, Croatto M, Pellegrino M.
Dermatol Reports. 2020 Jun 25;12(1):8642. doi: 10.4081/dr.2020.8642. eCollection 2020 Jun 25. Report / audit.
https://doi.org/10.4081/dr.2020.8642

Coronavirus disease 2019 (COVID-19) rash in a psoriatic patient treated with Secukinumab: is there a role for Interleukin 17?
Carugno A, Gambini DM, Raponi F, Vezzoli P, Robustelli Test E, Arosio MEG, Callegaro A, Sena P.
Dermatol Ther. 2020 Jul 12:e14011. doi: 10.1111/dth.14011. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.14011

Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Talamonti M, Tofani L, Bianchi L, Galluzzo M.
Arch Dermatol Res. 2020 Jul 9. doi: 10.1007/s00403-020-02103-z. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1007/s00403-020-02103-z

More on Covid-19 in immune-mediated inflammatory diseases.
Naldi L, Cazzaniga S.
N Engl J Med. 2020 Jul 10;383. pii: 10.1056/NEJMc2018011#sa1. doi: 10.1056/NEJMc2018011. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1056/NEJMc2018011

Patient´s perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice.
Rodríguez-Villa Lario A, Vega-Díez D, González-Cañete M, Polo-Rodríguez I, Piteiro-Bermejo AB, Herrero-Fernández M, Arévalo-Serrano J, Trasobares-Marugán L, Medina-Montalvo S.
J Dermatolog Treat. 2020 Jul 9:1-9. doi: 10.1080/09546634.2020.1790485. [Epub ahead of print] No abstract available. Retrospective chart review.
https://doi.org/10.1080/09546634.2020.1790485

How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
Jessica Chang TY, Pope JE.
Immunotherapy. 2020 Jul 9. doi: 10.2217/imt-2020-0153. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.2217/imt-2020-0153

Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.
Seirafianpour F, Sodagar S, Mohammad AP, Panahi P, Mozafarpoor S, Almasi S, Goodarzi A.
Dermatol Ther. 2020 Jul 8. doi: 10.1111/dth.13986. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/dth.13986

Risk of COVID-19 in dermatologic patients on long-term immunomodulatory therapy.
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML.
J Am Acad Dermatol. 2020 Jul 1. pii: S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.06.999

The risk of respiratory tract infections in psoriasis patients treated with IL-23-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Syed MN, Shin DB, Wan MT, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 Jul 2. pii: S0190-9622(20)32115-0. doi: 10.1016/j.jaad.2020.06.1014. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.06.1014

Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.
Ghazawi FM, Lim M, Dutz JP, Kirchhof MG.
Int J Dermatol. 2020 Jul 3. doi: 10.1111/ijd.15028. [Epub ahead of print]. Review.
https://doi.org/10.1111/ijd.15028

COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy versus apremilast in North Spain.
Queiro Silva R, Armesto S, González Vela C, Naharro Fernández C, González-Gay MA.
Dermatol Ther. 2020 Jul 3:e13961. doi: 10.1111/dth.13961. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13961

Global Hidradenitis Suppurativa COVID-19 Registry: A registry to inform data-driven management practices.
Naik HB, Alhusayen R, Frew J, Guilbault S, Ingram JR, Lowes MA, Marzano AV, Paul M, Villumsen B, Yannuzzi CA.
Br J Dermatol. 2020 Jun 29. doi: 10.1111/bjd.19345. [Epub ahead of print]. Research letter.
https://doi.org/10.1111/bjd.19345

Prior treatment with immunosuppressants among COVID-19 inpatients at one hospital in Spain.
Pastor-Nieto MA, Checa-Díaz P, González-Muñoz P, Martín-Fuentes A, Vergara-Sánchez A, Sánchez-Herreros C, Jiménez-Blázquez E, Cabana-Navia R, Martínez-Mariscal J, Cobo-Rodríguez P, Checa-Recio I, Gatica-Ortega ME, Torralba M, De Eusebio-Murillo E.
J Eur Acad Dermatol Venereol. 2020 Jun 28. doi: 10.1111/jdv.16798. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1111/jdv.16798

Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: A multicenter study in the Czech Republic.
Rob F, Hugo J, Tivadar S, Boháč P, Gkalpakiotis S, Vargová N, Arenbergerová M, Hercogová J.
J Eur Acad Dermatol Venereol. 2020 Jun 27. doi: 10.1111/jdv.16771. [Epub ahead of print]. Prospective research study.
https://doi.org/10.1111/jdv.16771

COVID-19 and psoriasis: Biologic treatment and challenges.
Ebrahimi A, Sayad B, Rahimi Z.
J Dermatolog Treat. 2020 Jun 29:1-14. doi: 10.1080/09546634.2020.1789051. [Epub ahead of print]. Review.
https://doi.org/10.1080/09546634.2020.1789051

Treatment of psoriasis - unburdened by fear during SARS-CoV2 menace.
Timis TL, Florian IA, Vesa SC, Orasan RI.
J Dermatolog Treat. 2020 Jun 27:1-10. doi: 10.1080/09546634.2020.1788704. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1080/09546634.2020.1788704

Using cyclosporine in the COVID era: an emergent need for caution.
Khurana A, Sethia K.
J Am Acad Dermatol. 2020 Jun 27. pii: S0190-9622(20)32090-9. doi: 10.1016/j.jaad.2020.06.990. [Epub ahead of print]. Commentary.
https://doi.org/10.1016/j.jaad.2020.06.990

COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: A tele-medicine experience.
Shahidi-Dadras M, Abdollahimajd F, Ohadi L, Tabary M, Araghi F, Mozafari N, Toosi P, Dadkhahfar S.
J Dermatolog Treat. 2020 Jun 27:1-7. doi: 10.1080/09546634.2020.1789041. [Epub ahead of print]. Cross-sectional study.
https://doi.org/10.1080/09546634.2020.1789041

COVID-19 infection on IL-23 inhibition.
Wang CJ, Truong AK.
Dermatol Ther. 2020 Jun 25. doi: 10.1111/dth.13893. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13893

Impact of the COVID-19 pandemic on immunomodulatory and immunosuppressive therapies in dermatology: Patient and physician attitudes in Argentina.
Zimman S, Cura MJ, Luna PC, Echeverría CM, Mazzuoccolo LD.
Actas Dermosifiliogr. 2020 Apr 29. pii: S0001-7310(20)30109-5. doi: 10.1016/j.ad.2020.04.004. [Epub ahead of print] English, Spanish. No abstract available. Cross-sectional study.
https://doi.org/10.1016/j.ad.2020.04.004

Organization of biologic therapy during the COVID-19 pandemic based on example of Dermatology Clinic Centre of Postgraduate Medical Education in Warsaw.
Dopytalska K, Mikucka-Wituszyńska A, Ciechanowicz P, Szczerba M, Szymańska E, Walecka I.
J Dermatolog Treat. 2020 Jun 22:1-15. doi: 10.1080/09546634.2020.1782822. [Epub ahead of print]. Report / commentary.
https://doi.org/10.1080/09546634.2020.1782822

Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.
Fougerousse AC, Perrussel M, Bécherel PA, Begon E, Pallure V, Zaraa I, Chaby G, Parier J, Kemula M, Mery-Bossard L, Poreaux C, Taieb C, Maccari F, Reguiai Z; GEM Resopso.
J Eur Acad Dermatol Venereol. 2020 Jun 21. doi: 10.1111/jdv.16761. [Epub ahead of print]. Multicentre, cross-sectional study.
https://doi.org/10.1111/jdv.16761

International collaboration and rapid harmonization across dermatologic COVID-19 registries.
Freeman EE, McMahon DE, Hruza GJ, Irvine AD, Spuls PI, Smith CH, Mahil SK, Castelo-Soccio L, Cordoro KM, Lara-Corrales I, Naik HB, Alhusayen R, Ingram JR, Feldman SR, Balogh EA, Kappelman MD, Wall D, Meah N, Sinclair R, Beylot-Barry M, Fitzgerald M, French LE, Lim HW, Griffiths CEM, Flohr C.
J Am Acad Dermatol. 2020 Jun 17. pii: S0190-9622(20)31148-8. doi: 10.1016/j.jaad.2020.06.050. [Epub ahead of print] No abstract available. Report / commentary.
https://doi.org/10.1016/j.jaad.2020.06.050

Treatment adherence in psoriatic patients during COVID-19 pandemic: Real-world data from a tertiary hospital in Greece''.
Vakirlis AE, Bakirtzi K, Papadimitriou I, Vrani F, Sideris N, Lallas A, Ioannides D, Sotiriou E.
J Eur Acad Dermatol Venereol. 2020 Jun 18. doi: 10.1111/jdv.16759. [Epub ahead of print]. Survey / observational study.
https://doi.org/10.1111/jdv.16759

Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab.
Facheris P, Valenti M, Pavia G, Gargiulo L, Narcisi A, Costanzo A, Borroni RG.
Int J Dermatol. 2020 Jun 18. doi: 10.1111/ijd.15008. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/ijd.15008

Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? : A systematic review.
Najar Nobar N, Goodarzi A.
Dermatol Ther. 2020 Jun 18:e13867. doi: 10.1111/dth.13867. [Epub ahead of print]. Systematic review.
https://doi.org/10.1111/dth.13867

Comment on "Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment".
Farabi B, Bhargava S, Goldust M, Atak MF.
Dermatol Ther. 2020 Jun 14:e13840. doi: 10.1111/dth.13840. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13840

Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.
Kearns DG, Uppal S, Chat VS, Wu JJ.
J Am Acad Dermatol. 2020 Jun 10. pii: S0190-9622(20)31075-6. doi: 10.1016/j.jaad.2020.06.015. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.06.015

COVID-19 era: A chance to learn something new about monitoring psoriatic patients in biological therapy.
Filippi F, Loi C, Evangelista V, Bardazzi F.
Dermatol Ther. 2020 Jun 10:e13805. doi: 10.1111/dth.13805. [Epub ahead of print] No abstract available. Report / audit.
https://doi.org/10.1111/dth.13805

Biologic agents in psoriasis: our experience during coronavirus infection.
Strippoli D, Barbagallo T, Prestinari F, Russo G, Fantini F.
Int J Dermatol. 2020 Jun 9. doi: 10.1111/ijd.15002. [Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1111/ijd.15002

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Galluzzo M, Tofani L, Bianchi L, Talamonti M.
Expert Opin Biol Ther. 2020 Jun 8. doi: 10.1080/14712598.2020.1779217. [Epub ahead of print] No abstract available. Commentary/ cohort study.
https://doi.org/10.1080/14712598.2020.1779217

Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience.
Rossi M, Rovati C, Arisi M, Soglia S, Calzavara-Pinton P.
Dermatol Ther. 2020 Jun 4:e13765. doi: 10.1111/dth.13765. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13765

Rate of patient-driven biologic treatment discontinuation during the COVID-19 pandemic in 2 academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 Jun 1:1203475420930226. doi: 10.1177/1203475420930226. [Epub ahead of print] No abstract available. Multicentre retrospective case review.
https://doi.org/10.1177/1203475420930226

Psoriasis, biologic therapy, and the pandemic of the 21st century.
Nogueira M, Vender R, Torres T.
Drugs Context. 2020 May 14;9. pii: 2020-4-10. doi: 10.7573/dic.2020-4-10. eCollection 2020. Editorial.
https://doi.org/10.7573/dic.2020-4-10

Covid-19 infection in psoriasis patients treated with cyclosporin.
Di Lernia V, Goldust M, Feliciani C.
Dermatol Ther. 2020 Jun 1. doi: 10.1111/dth.13739. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13739

Psoriasis, COVID-19 and acute respiratory distress syndrome: focusing on the risk of concomitant biological treatment.
Magnano M, Balestri R, Bardazzi F, Mazzatenta C, Girardelli CR, Rech G.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13706. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1111/dth.13706

Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult psoriasis during COVID-19 pandemic.
Melis D, Mugheddu C, Sanna S, Atzori L, Rongioletti F.
Dermatol Ther. 2020 May 30:e13722. doi: 10.1111/dth.13722. [Epub ahead of print]. Case series.
https://doi.org/10.1111/dth.13722

Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab.
Valenti M, Facheris P, Pavia G, Gargiulo L, Borroni RG, Costanzo A, Narcisi A.
Dermatol Ther. 2020 May 30. doi: 10.1111/dth.13708. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13708

Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.
Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P.
Ann Rheum Dis. 2020 May 28. pii: annrheumdis-2020-217903. doi: 10.1136/annrheumdis-2020-217903. Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1136/annrheumdis-2020-217903

Novel coronavirus disease (COVID-19) and biologic therapy for psoriasis: Successful recovery in two patients after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 May 29. doi: 10.1007/s13555-020-00394-8. [Epub ahead of print]. Case reports.
https://doi.org/10.1007/s13555-020-00394-8

Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days.
Karadag AS, Aslan Kayıran M, Lotti T, Wollina U.
Dermatol Ther. 2020 May 27:e13686. doi: 10.1111/dth.13686. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13686

Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Ricardo JW, Lipner SR.
Dermatol Ther. 2020 May 27. doi: 10.1111/dth.13687. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13687

Use of systemic therapies for psoriasis in the COVID-19 era.
Kearns DG, Uppal S, Chat VS, Wu JJ.
J Dermatolog Treat. 2020 May 27:1-14. doi: 10.1080/09546634.2020.1775774. [Epub ahead of print]. Review of guidelines.
https://doi.org/10.1080/09546634.2020.1775774

Preliminary data suggests that biologics in dermatology are not associated with adverse COVID-19 outcomes.
Nassim D, Jfri A, Litvinov IV, Netchiporouk E.
J Cutan Med Surg. 2020 May 25:1203475420929250. doi: 10.1177/1203475420929250. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1177/1203475420929250

Apremilast as a potential treatment option for COVID-19: no symptoms of infection in a psoriatic patient.
Yu Olisova O, Anpilogova EM, Svistunova DA.
Dermatol Ther. 2020 May 24:e13668. doi: 10.1111/dth.13668. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13668

Moderate to severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.
Giulia R, Alice R, Teresa FM, Paolo D, Simone R.
Dermatol Ther. 2020 May 24. doi: 10.1111/dth.13680. [Epub ahead of print] No abstract available. Retrospective cohort study.
https://doi.org/10.1111/dth.13680

Management of pemphigus in COVID-19 pandemic era; a review article.
Abdollahimajd F, Shahidi-Dadras M, M Robati R, Dadkhahfar S.
Arch Acad Emerg Med . 2020 Apr 18;8(1):e51. eCollection 2020. Review.
http://journals.sbmu.ac.ir/aaem/index.php/AAEM/article/view/663/789

Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability.
Khurana A, Saxena S.
Dermatol Ther. 2020 May 21. doi: 10.1111/dth.13639. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13639

Patient-driven discontinuation of dupilumab during the COVID-19 pandemic in two academic hospital clinics at the University of Toronto.
Georgakopoulos JR, Yeung J.
J Cutan Med Surg. 2020 May 20:1203475420930223. doi: 10.1177/1203475420930223. [Epub ahead of print] No abstract available. Retrospective cross-sectional study.
https://doi.org/10.1177/1203475420930223

Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
Rosi E, Pimpinelli N, Prignano F.
J Dermatolog Treat. 2020 May 20:1-4. doi: 10.1080/09546634.2020.1771256. [Epub ahead of print] No abstract available. Letter / commentary.
https://doi.org/10.1080/09546634.2020.1771256

COVID-19 and dermatology: A comprehensive guide for dermatologists.
Fahmy DH, El-Amawy HS, El-Samongy MA, Foud AA, Soliman SH, El-Kady A, Farnetani F, Conti A, Zoeir A, Eissa A, Eissa R, Puliatti S, Sighinolfi MC, Rocco B, Pellacani G.
J Eur Acad Dermatol Venereol. 2020 May 19. doi: 10.1111/jdv.16545. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/jdv.16545

Active implications for dermatologists in "SARS-CoV-2 era": Personal experience and review of literature.
Campanati A, Brisigotti V, Diotallevi F, D'Agostino GM, Paolinelli M, Radi G, Rizzetto G, Sapigni C, Tagliati C, Offidani A.
J Eur Acad Dermatol Venereol. 2020 May 19. doi: 10.1111/jdv.16646. [Epub ahead of print]. Review / commentary.
https://doi.org/10.1111/jdv.16646

Retrospective analysis of smell and taste disturbances associated with dermatological medications reported to the United States Food and Drug Administration and relevance to COVID-19 infections.
Wang Y, Lipner SR.
J Am Acad Dermatol. 2020 May 17. doi: 10.1016/j.jaad.2020.05.057. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.05.057

Opportunistic virus infections in psoriasis patients: the safer alternative of apremilast.
Armesto S, González Vela C, González López MA.
Dermatol Ther. 2020 May 18:e13618. doi: 10.1111/dth.13618. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13618

Immunosuppressive treatment for systemic sclerosis - therapeutic challenges during the COVID-19 pandemic.
Blicharz L, Czuwara J, Samochocki Z, Goldust M, Olszewska M, Rudnicka L.
Dermatol Ther. 2020 May 19:e13619. doi: 10.1111/dth.13619. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1111/dth.13619

Evidenced-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19.
Galimberti F, McBride J, Cronin M, Li Y, Fox J, Abrouk M, Herbst A, Kirsner RS.
Clin Dermatol. 2020 May 14. doi: 10.1016/j.clindermatol.2020.05.003. [Epub ahead of print]. Review / recommendations.
https://doi.org/10.1016/j.clindermatol.2020.05.003

Safety of dupilumab in atopic patients during COVID-19 outbreak.
Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G.
J Dermatolog Treat. 2020 May 18:1-5. doi: 10.1080/09546634.2020.1771257. [Epub ahead of print] No abstract available. Survey / cross-sectional study.
https://doi.org/10.1080/09546634.2020.1771257

The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic.
Wan MT, Shin DB, Winthrop KL, Gelfand JM.
J Am Acad Dermatol. 2020 May 13. pii: S0190-9622(20)30866-5. doi: 10.1016/j.jaad.2020.05.035. [Epub ahead of print] No abstract available. Meta-analysis.
https://doi.org/10.1016/j.jaad.2020.05.035

COVID-19 knowledge prevents biologics discontinuation: data from an Italian multi-center survey during RED-ZONE declaration.
Bragazzi NL, Riccò M, Pacifico A, Malagoli P; COVID19 Dermatological Task Force, Young Dermatologists Italian Network, Kridin K, Pigatto P, Damiani G.
Dermatol Ther. 2020 May 16:e13508. doi: 10.1111/dth.13508. [Epub ahead of print]. Cross-sectional study / survey.
https://doi.org/10.1111/dth.13508

A survey of psoriasis patients on biologics during COVID-19: a single centre experience.
Burlando M, Carmisciano L, Cozzani E, Parodi A.
J Dermatolog Treat. 2020 May 14:1-3. doi: 10.1080/09546634.2020.1770165. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1080/09546634.2020.1770165

Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral centre of Southern Italy.
Marasca C, Ruggiero A, Megna M, Annunziata MC, Fabbrocini G.
J Dermatolog Treat. 2020 May 13:1-3. doi: 10.1080/09546634.2020.1769828. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1769828

COVID-19 in an elderly patient treated with secukinumab.
Di Lernia V, Bombonato C, Motolese A.
Dermatol Ther. 2020 May 13:e13580. doi: 10.1111/dth.13580. [Epub ahead of print] No abstract available. Case report.
https://doi.org/10.1111/dth.13580

Is the coronavirus (COVID-19) pandemic an indication to temporarily modify dermatological management plans?
Shanshal M.
J Drugs Dermatol. 2020 Apr 1;19(4):436. No abstract available. Commentary.
http://jddonline.com/articles/dermatology/S1545961620P0436X

Patient-driven discontinuation of apremilast during the COVID-19 pandemic in two Canadian academic hospital clinics and one community practice.
Georgakopoulos JR, Vender R, Yeung J. Multicenter retrospective study.
J Cutan Med Surg. 2020 May 12:1203475420928382. doi: 10.1177/1203475420928382. [Epub ahead of print]
https://doi.org/10.1177/1203475420928382

COVID-19 and biologics for psoriasis: a high-epidemic area experience - Bergamo, Lombardy, Italy.
Carugno A, Gambini DM, Raponi F, Vezzoli P, Locatelli AGC, Di Mercurio M, Test ER, Sena P.
J Am Acad Dermatol. 2020 May 6. pii: S0190-9622(20)30819-7. doi: 10.1016/j.jaad.2020.04.165. [Epub ahead of print] No abstract available. Case reports & commentary.
https://doi.org/10.1016/j.jaad.2020.04.165 

Systemic immunobiological, immunosuppressant and oncologic agents for the treatment of dermatologic diseases during the SARS-Cov-2 (COVID19) pandemic emergency: A quick review for a quick consultation.
Paolino G, Mercuri SR, Bearzi P, Mattozzi C.
Dermatol Ther. 2020 May 8:e13537. doi: 10.1111/dth.13537. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13537

SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.
Caroppo F, Biolo G, Belloni Fortina A.
J Eur Acad Dermatol Venereol. 2020 May 9. doi: 10.1111/jdv.16619. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16619

Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern.
Rudnicka L, Goldust M, Glowacka P, Sikora M, Sar-Pomian M, Rakowska A, Samochocki Z, Olszewska M.
J Am Acad Dermatol. 2020 May 3. pii: S0190-9622(20)30775-1. doi: 10.1016/j.jaad.2020.04.153. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.04.153

Clinical considerations for managing dermatology patients on systemic immunosuppressive and/or biologic therapy during COVID-19 pandemic.
Sanchez DP, Kirsner RS, Lev-Tov H.
J Am Acad Dermatol. 2020 May 4. pii: S0190-9622(20)30765-9. doi: 10.1016/j.jaad.2020.04.143. [Epub ahead of print] No abstract available. Review / commentary.
https://doi.org/10.1016/j.jaad.2020.04.143

Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs.
Conti A, Lasagni C, Bigi L, Pellacani G.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16587. [Epub ahead of print]. Case series.
https://doi.org/10.1111/jdv.16587

Improvement of SARS-CoV2 symptoms following guselkumab injection in a psoriatic patient.
Benhadou F, Del Marmol V.
J Eur Acad Dermatol Venereol. 2020 May 7. doi: 10.1111/jdv.16590. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16590

Covid-19 in immune-mediated inflammatory diseases - Case series from New York.
Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU.
N Engl J Med. 2020 Apr 29. doi: 10.1056/NEJMc2009567. [Epub ahead of print] No abstract available. Case series.
https://doi.org/10.1056/NEJMc2009567

Dupilumab and COVID-19: what should we expect?
Patruno C, Stingeni L, Fabbrocini G, Hansel K, Napolitano M.
Dermatol Ther. 2020 May 2. doi: 10.1111/dth.13502. [Epub ahead of print]. Commentary.
https://doi.org/10.1111/dth.13502

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Balestri R, Rech G, Girardelli CR.
J Eur Acad Dermatol Venereol. 2020 May 2. doi: 10.1111/jdv.16571. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16571

Biologic therapy for psoriasis during the COVID-19 outbreak: the choice is to weigh risks and benefits.
Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.
Dermatol Ther. 2020 May 1:e13490. doi: 10.1111/dth.13490. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13490

Comment on "Antipsoriatic treatments during COVID-19 outbreak".
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 May 1:e13491. doi: 10.1111/dth.13491. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13491

Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.
Balestri R, Rech G, Girardelli CR.
J Eur Acad Dermatol Venereol. 2020 May 2. doi: 10.1111/jdv.16578. [Epub ahead of print]. Case report / commentary.
https://doi.org/10.1111/jdv.16578

COVID-19: a case for inhibiting IL-17?
Pacha O, Sallman MA, Evans SE.
Nat Rev Immunol. 2020 May 1. doi: 10.1038/s41577-020-0328-z. [Epub ahead of print] No abstract available. Commentary.
https://doi.org/10.1038/s41577-020-0328-z

Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration.
Damiani G, Pacifico A, Bragazzi NL, Malagoli P.
Dermatol Ther. 2020 May 1:e13475. doi: 10.1111/dth.13475. [Epub ahead of print]. Cohort study.
https://doi.org/10.1111/dth.13475

Dermatology patients' knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic.
Keeling E, Daly S, McKenna DB.
Dermatol Ther. 2020 May 1:e13488. doi: 10.1111/dth.13488. [Epub ahead of print] No abstract available. Survey.
https://doi.org/10.1111/dth.13488

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters A, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls P, Griffiths CEM, Barker J, Irvine AD, Smith CH; Secure-AD, PsoPROTECT study groups.
Br J Dermatol. 2020 Apr 29. doi: 10.1111/bjd.19161. [Epub ahead of print]. Letter/commentary.
https://doi.org/10.1111/bjd.19161

The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.
Gisondi P, Facheris P, Dapavo P, Piaserico S, Conti A, Naldi L, Cazzaniga S, Malagoli P, Costanzo A.
Br J Dermatol. 2020 Apr 28. doi: 10.1111/bjd.19158. [Epub ahead of print]. Multicentre observational study.
https://doi.org/10.1111/bjd.19158

Biologics for psoriasis in COVID-19 era: what do we know?
Megna M, Napolitano M, Patruno C, Fabbrocini G.
Dermatol Ther. 2020 Apr 27:e13467. doi: 10.1111/dth.13467. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13467

No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.
Carugno A, Raponi F, Locatelli AG, Vezzoli P, Gambini DM, Di Mercurio M, Robustelli Test E, Sena P.
J Eur Acad Dermatol Venereol. 2020 Apr 27. doi: 10.1111/jdv.16552. [Epub ahead of print]. Case series.
https://doi.org/10.1111/jdv.16552

Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment.
Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G.
J Am Acad Dermatol. 2020 Apr 21. pii: S0190-9622(20)30701-5. doi: 10.1016/j.jaad.2020.04.085. [Epub ahead of print] No abstract available. Cross-sectional study.
https://doi.org/10.1016/j.jaad.2020.04.085

Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.
Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S.
J Eur Acad Dermatol Venereol. 2020 Apr 24. doi: 10.1111/jdv.16527. [Epub ahead of print]. Case reports.
https://doi.org/10.1111/jdv.16527

Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?
Alpalhão M, Filipe P.
J Dermatolog Treat. 2020 Apr 23:1-8. doi: 10.1080/09546634.2020.1760195. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1760195

COVID-19 and psoriasis : should we fear for patients treated with biologics?
Amerio P, Prignano F, Giuliani F, Gualdi G.
Dermatol Ther. 2020 Apr 20. doi: 10.1111/dth.13434. [Epub ahead of print]. Review.
https://doi.org/10.1111/dth.13434

Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?
Di Altobrando A, Patrizi A, Bardazzi F.
J Eur Acad Dermatol Venereol. 2020 Apr 17. doi: 10.1111/jdv.16491. [Epub ahead of print]. Letter.
https://doi.org/10.1111/jdv.16491

Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears.
Megna M, Ruggiero A, Marasca C, Fabbrocini G.
J Dermatolog Treat. 2020 Apr 17:1-5. doi: 10.1080/09546634.2020.1757605. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1757605

Successful guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic.
Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F.
Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print]. Case report.
https://doi.org/10.1111/dth.13433

Novel coronavirus disease (COVID-19) and biologic therapy in psoriasis: Infection risk and patient counseling in uncertain times.
Brownstone ND, Thibodeaux QG, Reddy VD, Myers BA, Chan SY, Bhutani T, Liao W.
Dermatol Ther (Heidelb). 2020 Apr 16. doi: 10.1007/s13555-020-00377-9. [Epub ahead of print]. Commentary.
https://doi.org/10.1007/s13555-020-00377-9

Psoriasis and psoriatic arthritis: how to manage immunosuppressants in COVID-19 days.
Coletto LA, Favalli EG, Caporali R.
Dermatol Ther. 2020 Apr 14:e13415. doi: 10.1111/dth.13415. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1111/dth.13415

SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor.
Messina F, Piaserico S.
J Eur Acad Dermatol Venereol. 2020 Apr 15. doi: 10.1111/jdv.16468. [Epub ahead of print]. Case report.
https://doi.org/10.1111/jdv.16468

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.
Blaszczak A, Trinidad JCL, Cartron AM.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30606-X. doi: 10.1016/j.jaad.2020.04.030. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.030

The management of biologics in dermatologic patients in the 2019-nCoV era.
Plachouri KM, Georgiou S.
J Dermatolog Treat. 2020 Apr 13:1. doi: 10.1080/09546634.2020.1749544. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1749544

Reply to "COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution".
Lebwohl M, Rivera-Oyola R, Murrell DF.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30528-4. doi: 10.1016/j.jaad.2020.03.103. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.03.103

Reply to: "Biologics for psoriasis during COVID-19 outbreak".
Murrell DF, Rivera-Oyola R, Lebwohl M.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30554-5. doi: 10.1016/j.jaad.2020.04.014. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.014

Biologics for psoriasis during COVID-19 outbreak.
Di Lernia V.
J Am Acad Dermatol. 2020 Apr 10. pii: S0190-9622(20)30543-0. doi: 10.1016/j.jaad.2020.04.004. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1016/j.jaad.2020.04.004

COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australia/New Zealand consensus statement.
Wang C, Rademaker M, Baker C, Foley P.
Australas J Dermatol. 2020 Apr 7. doi: 10.1111/ajd.13313. [Epub ahead of print]. Guideline/consensus statement.
https://doi.org/10.1111/ajd.13313

SECURE-Psoriasis: A de-identified registry of psoriasis patients diagnosed with COVID-19.
Balogh EA, Heron C, Feldman SR, Huang WW.
J Dermatolog Treat. 2020 Apr 8:1-2. doi: 10.1080/09546634.2020.1753996. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1753996

Biological treatment use amid the COVID-19 era, a close look at the unresolved perplexity.
Shanshal M.
J Dermatolog Treat. 2020 Apr 7:1-9. doi: 10.1080/09546634.2020.1752886. [Epub ahead of print] No abstract available. Letter.
https://doi.org/10.1080/09546634.2020.1752886

Biologic therapy for psoriasis during the covid-19 outbreak is not a choice.
Bardazzi F, Loi C, Sacchelli L, Di Altobrando A.
J Dermatolog Treat. 2020 Apr 6:1-2. doi: 10.1080/09546634.2020.1749545. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1749545

COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution.
Kansal NK.
J Am Acad Dermatol. 2020 Apr 1. pii: S0190-9622(20)30502-8. doi: 10.1016/j.jaad.2020.03.079. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.079

Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic.
Shah P, Zampella JG.
J Am Acad Dermatol. 2020 Mar 31. pii: S0190-9622(20)30478-3. doi: 10.1016/j.jaad.2020.03.056. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.056

Comment on "COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action".
Abdelmaksoud A, Goldust M, Vestita M.
Dermatol Ther. 2020 Apr 1:e13360. doi: 10.1111/dth.13360. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13360

Antipsoriatic treatments during COVID-19 outbreak.
Di Lernia V.
Dermatol Ther. 2020 Mar 29:e13345. doi: 10.1111/dth.13345. [Epub ahead of print] No abstract available.
https://doi.org/10.1111/dth.13345

Biological treatment during COVID-19 outbreak.
Sriwijitalai W, Wiwanitkit V.
J Dermatolog Treat. 2020 Mar 28:1. doi: 10.1080/09546634.2020.1749548. [Epub ahead of print] No abstract available.
https://doi.org/10.1080/09546634.2020.1749548

COVID-19 and immunomodulator/immunosuppressant use in dermatology.
Price KN, Frew JW, Hsiao JL, Shi VY.
J Am Acad Dermatol. 2020 Mar 26. pii: S0190-9622(20)30466-7. doi: 10.1016/j.jaad.2020.03.046. [Epub ahead of print] No abstract available.
https://doi.org/10.1016/j.jaad.2020.03.046 

Advice regarding COVID-19 and use of immunomodulators, in patients with severe dermatological diseases.
Rademaker M, Baker C, Foley P, Sullivan J, Wang C.
Australas J Dermatol. 2020 Mar 26. doi: 10.1111/ajd.13295. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/32219857

Should biologics for psoriasis be interrupted in the era of COVID-19?
Lebwohl M, Rivera-Oyola R, Murrell DF.
J Am Acad Dermatol. 2020 Mar 18. pii: S0190-9622(20)30445-X. doi: 10.1016/j.jaad.2020.03.031. [Epub ahead of print]
https://doi.org/10.1016/j.jaad.2020.03.031

Should patients stop their biologic treatment during the COVID-19 pandemic.
Bashyam AM, Feldman SR.
J Dermatolog Treat. 2020 Mar 19:1-2. doi: 10.1080/09546634.2020.1742438. [Epub ahead of print]
https://doi.org/10.1080/09546634.2020.1742438

COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.
Conforti C, Giuffrida R, Dianzani C, Di Meo N, Zalaudek I.
Dermatol Ther. 2020 Mar 11:e13298. doi: 10.1111/dth.13298. [Epub ahead of print]
https://doi.org/10.1111/dth.13298

 

Back to CEBD Coronavirus Dermatology Resource Homepage

Centre of Evidence Based Dermatology

The University of Nottingham
King's Meadow Campus
Lenton Lane
Nottingham, NG7 2NR


telephone: +44 (0) 115 823 1048
email:cebd@nottingham.ac.uk